Panlong Pharmaceuticals Convertible Bonds Open for Subscription to Accelerate Main Business Expansion and Upgrading

　　On March 2, the online roadshow for the issuance of convertible bonds of Panlong Pharmaceuticals was successfully held, and the company's convertible bonds are available for subscription today.

　　The chairman and general manager of Panlong Pharmaceuticals, Xie Xiaolin, and other key members of the company's management and the sponsor of the issue (lead underwriter), CTS, participated in the online roadshow and conducted real-time online communication with investors.

　　The company issued convertible bonds to raise 276 million yuan to strengthen the business extension and upgrade on the basis of the main business, mainly invested in the construction of centralized preparation center in medical institutions in Shaanxi Province and the upgrade of quality inspection and testing sharing platform of Panlong Pharmaceutical.

　　The company said that it has signed R&D and production orders with 21 medical institutions and cooperation intentions with more than 70 medical institutions. After the convertible bond issuance project is landed, the company will accelerate the construction of the in-hospital formulation project so that the project can generate economic and social benefits as soon as possible.

　　Founded in 1997, Panlong Pharmaceutical was listed on the Shenzhen Stock Exchange in November 2017.

　　After more than 20 years of development, the company has gradually formed a business development model integrating standardized cultivation of medicinal herbs, pharmaceutical production, R&D, sales and pharmaceutical logistics, and has an excellent management team with professional theories, industry experience, management innovation and common values, and has gradually established a more complete corporate governance system and internal control measures to ensure the steady and healthy development of the company.

　　The company has 16 production lines of tablets and capsules that have passed the new version of national GMP certification, as well as supporting testing and research equipment. The company has a powerful product lineup of 9 functional categories and more than 100 product specifications, with an annual production and operation scale of 1 billion yuan.

　　Xie Xiaolin, chairman and general manager of Panlong Pharmaceuticals, said in response to investors' questions that this year, the company proposed a strategic positioning of focusing on its main business, practicing internal strength, scientific and technological innovation and international vision, and the company will follow the national "One Belt and One Road" policy to inherit Chinese medicine culture, let the world understand Chinese medicine and let Chinese medicine go global.

　　The company plans to set up Internet hospitals and Chinese herbal medicine planting and R&D in countries along the "Belt and Road", and also plans to establish R&D institutions with relevant universities overseas, so that the company can step into the international vision as soon as possible according to the strategy of "grasping the frontier and combining innovation and imitation".

　　Wu Jie, deputy general manager and secretary of the board of directors of Panlong Pharmaceuticals, said in response to investors' questions that the company has developed big health products such as Panlong Hydration Repair Mask, Panlong Seven Roses Essential Oil and Long Guifei Medical Sodium Hyaluronate Repair Patch.

　　The company's big health products are currently sold in Jingdong Mall, Taobao, Jindo platform, Weimeng, shake store (Pan Long Yun Kang), shake store (Pan Long Jiu Mei), WeChat small store a total of seven platforms, the company has been actively promoting the layout of big health products online and offline, so that more Pan Long health products popular end consumers.

　　Wu Jie said that the fund-raising investment project is in line with the relevant national industrial policies and the development direction of the company's future overall strategy, and has good market development prospects and economic benefits.

　　The implementation of the fund-raising investment project is conducive to enhancing the company's production capacity, optimizing the product structure, improving the overall profitability of the company, enhancing the core competitiveness of the company, consolidating and improving the company's market position and market influence in the industry, and laying a solid foundation for the long-term sustainable development of the company.